source
- Opinion: Mifepristone court ruling makes drug development riskier for everyoneThe 5th Circuit’s ruling on mifepristone “is bad for health care access, and it’s also bad for innovation,” writes Grace E. Colón.STAT · 2mo ago↗ source
- FDA search for new CBER head focused on small group of final candidatesThe FDA has narrowed its search for a new leader of its Center for Biologics Evaluation and Research to three or four final candidates, according to a person familiar with the matter. The agency ho…Endpoints · 2mo ago↗ source
- Supreme Court restores mifepristone access by mailThe Supreme Court restored mail ordering of mifepristone, reversing a federal appeals court’s stay. The decision Monday came after makers of the pill asked for an immediate response to a ruling ...